chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Swelling of left armpit underneath injection site; Arm feels very heavy; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 17 year-old male patient received bnt162b2 (BNT162B2), administered in arm left, administration date 09Oct2021 13:00 (Lot number: FF 2587) at the age of 17 years as dose 1, single for covid-19 immunisation. The patient's relevant medical history was not reported. There were no concomitant medications. The following information was reported: PERIPHERAL SWELLING (non-serious) with onset 10Oct2021 18:00, outcome "unknown", described as "Swelling of left armpit underneath injection site"; LIMB DISCOMFORT (non-serious) with onset 10Oct2021 18:00, outcome "unknown", described as "Arm feels very heavy". Therapeutic measures were not taken as a result of peripheral swelling, limb discomfort. No follow-up attempts are possible. No further information is expected.
got the worst case imaginable from the shot/Suspected vaccination failure; got the worst case imaginable from the shot; This case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure and shingles were unknown.   The reporter considered the vaccination failure and shingles to be related to Shingles vaccine.     Additional Information: GSK receipt date: 11-June-2022 Reporter's comment: This case was reported by a patient's cousin via interactive digital media. The patient got the worst shingles case imaginable from the shot.  Additional Supportive Information: This case was considered as suspected vaccination failure since the details regarding completion of primary vaccination schedule, time to onset and laboratory confirmation of shingles not provided.
Patient received COVID Pfizer monovalent vaccine along with Fluzone HD vaccine at a routine appointment on 9/21/23. On the morning of 9/24/23 he began noticing symptoms of gait disturbance and generalized weakness. He presented to an urgent care on 9/25/23 with continued symptoms, worse balance and new speech difficulties with difficulty finding words and slight slurred speech. Urgent care sent him to Emergency Medical Center where he was assessed and found to ha ve and intraparenchymal hemorrhage in the left basal ganglia on CT. MRI brain confirmed a left acute thalamic intraparenchymal hematoma.
PATIENT HAS RECEIVED TWO DIFFERENT COVID VACCINES. PATIENT CAME IN FOR JANSSEN COVID VACCINE AT OUR STORE AND SAID TO MULTIPLE WORKERS HE HAD NOT RECEIVED ANY OTHER COVID VACCINE. UPON ENTERING THE SHOT INTO MCIR AFTER ADMINISTRATION, WE SAW PATIENT HAD PREVIOUSLY RECEIVED FIRST DOSE OF MODERNA FROM .
This spontaneous report as received from a registered nurse refers to a patient of unknown age. On 14-JUL-2017 the patient was vaccinated with GARDASIL 9 lot # M040412 that underwent a temperature excursion on 17-JUN-2017. No adverse effects reported.
Patient felt dizzy and felt like passing out. V.S. taken Pulse 42, became clammy, diaphoretic, and very weak. Rapid Response called, patient to the Emergency Room.
Fever in excess of 102, violent nausea, multiple nausea events, severe headache and pain.
Upper respiratory infection symptoms 24 hours after vaccine. Fine red raised rash with itching noted on upper chest initially, then legs, arms, and buttocks 48 hours after vaccine. Topical hydrocortisone cream and Benadryl 50mg. orally (both OTC) taken
A couple of hours after injection, began feeling very tired, my neck began to get stiff, as well as stiffness from my neck down my back.  Nausea and migraine began at this same time and are still an issue (today) 3 days later.   Also, the lack of energy has been constant.
itchiness at the injection site; Redness injection site; swelling injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PRURITUS (itchiness at the injection site), VACCINATION SITE ERYTHEMA (Redness injection site) and VACCINATION SITE SWELLING (swelling injection site) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 06-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-Jan-2021, the patient experienced VACCINATION SITE PRURITUS (itchiness at the injection site), VACCINATION SITE ERYTHEMA (Redness injection site) and VACCINATION SITE SWELLING (swelling injection site). At the time of the report, VACCINATION SITE PRURITUS (itchiness at the injection site), VACCINATION SITE ERYTHEMA (Redness injection site) and VACCINATION SITE SWELLING (swelling injection site) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were provided.  No treatment information provided
Severe shaking during teh night with chest congestion and headache. Resolved by teh following day at 3pm
Nausea, sweating, vomiting, eyes itching and watering and opposite hand from injections site with finger swelling and itching. On 11/28/2012 reported fever of 99 to 101.
This spontaneous report was received from a nurse, referring to a patient of unknown age and gender. The patient's historical drugs, medical history, concomitant therapies, drugs allergies and concurrent conditions were not reported. On 22-AUG-2018, the patient were vaccinated with improperly stored doses of ZOSTAVAX lot # N026816, expiration date 25-DEC-2018, for prophylaxis (strength, dose, route and frequency were not reported). The vaccine was reconstituted with a properly stored sterile diluent (MERCK STERILE DILUENT) lot # N023306, expiration date 20-JAN-2020. The temperature excursion was of 15 Fahrenheit degrees (°F) to 46°F, during 6 days. However, a previous temperature excursion of 47°F to 77°F for 1 hour was also reported. A digital data logger was involved. No adverse effects were reported.
Myasthenia gravis exacerbation with head drop, dysphonia, and leg weakness.
Tachycardia with incomplete right bundle branch block with PVC's. Young healthy 29-year-old nurse with no co- morbidities or previous health history.
patient noted sweating having tingling to fingers low blood pressure blurred vision fluids encouraged sweet snacks offered,.
HAD THE SHOT AND STILL GOT THEM/Suspected Vaccination Failure; HAD THE SHOT AND STILL GOT THEM; This case was reported by a consumer via interactive digital media and described the occurrence of suspected vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure and shingles were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine.  Additional details were reported as follows: This case was reported by patient for himself/herself. The age at vaccination was not reported. The patient had the shot and still got shingles.  The follow-up would not possible as no contact details were available. This case was considered as suspected vaccination failure as details regarding completion of primary vaccination schedule, time to onset and laboratory confirmation for shingles were unknown at the time of reporting.
Received 2nd dose of Moderna 3 months after first dose. Fell asleep around 11 pm, woke up at midnight with severe headache, shaking with fever of 103, vaccination site hurt. Unable to sleep the rest of the night. Just thought it was interesting because of the interval from the first to second dose and the intensity of the reaction. Fever and headache still happening at around 1 pm right now,  but not so bad.
pt recvd vax & devel central scotoma & was seen by MD who dx chorioretinitis; also devel a fever & arthritis; sx persisted for approx 2 months & pt recovered; lab eval in 1992 revealed a neg measles antibody titer;
30 minute after the vaccine administration headache 01/15/2021;, 01/18/2021  2 days after the vaccine administration chills and body malaise; 01/19/2021 tested for COVID and was tested positive at  drive thru COVID testing at college
Patient unable to lift right arm where HIB inj. was given. Pt received wrong immunizations. Pt is a 6 y/o male.
2 days after 1st Covid  vaccination my right arm at the site of the injection,  the muscle became very sore and any exertion such as shoveling snow or lifting is very hard..  The muscle is always sore,  even laying on my right side when sleeping  is uncomfortable and    will wake me up from sleeping
This spontaneous report as received from a licensed practical nurse refers to a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant medications were not reported. On an unknown date, the patient was vaccinated with an improperly stored dose of (Oka/Merck) VARIVAX (lot # K003420 with expiration date 06-MAR-2016; dose and route of administration were not reported). No adverse effects were reported. Additional information has been requested.
Left arm 3" below site of injection. 3" red area warm to touch, sore; started 10/28/02 increasing. Complained of body aches, headache, temperature 97.5. Ibuprofen given. Ice pack to arm.
Information has been received from a physician concerning a 74 year old female who on 20-JUL-2007 was inadvertently vaccinated with a dose of Zostavax (Oka/Merck) instead of her second dose of Varivax (Oka/Merck).  The patient received a first dose of Varivax (Oka/Merck) on 21-JUN-2007, and was due for the second dose on 20-JUL-2007.  Unspecified medical attention was sought.  There was no additional information provided. There was no product quality complaint involved.  Additional information has been requested.
received an expired dose of Boostrix; This case was reported by a other health professional via call center representative and described the occurrence of expired vaccine used in a 71-year-old female patient who received DTPa (Reduced antigen) (Boostrix) (batch number 53bf4, expiry date 14th August 2021) for prophylaxis.   On 8th March 2022, the patient received Boostrix. On 8th March 2022, unknown after receiving Boostrix, the patient experienced expired vaccine used. On an unknown date, the outcome of the expired vaccine used was unknown.  Additional details were provided as follows: The patient received an expired dose of Boostrix, which led to expired vaccine used. The reporter was contacted after the call to get follow up consent but could not reach out to the reporter.
West Nile Virus; slept all the time; ran 99 fever and tired; ran 99 fever and tired; encephalitis; This is a spontaneous report from a contactable consumer (patient). An 84-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE) dose 3 via an unspecified route of administration, administered in arm left on 20Sep2021 01:30 PM (at the age of 84 years old, Lot Number: FC3183) as dose 3 (booster), single for covid-19 immunisation. Medical history included cll, bovine heart valve. The patient's concomitant medications were not reported. The patient previously took Dose 1 of BNT162B2 in arm left 0.3ML on 04Feb2021 (lot number EN9581); Dose 2 of BNT162B2 in Arm Left 0.3ML on 23Feb2021 (lot number EN6202) and ran a slight fever on 17Sep2021 after coming from gym. The patient previously received unspecified drug and experienced allergy. On 21Sep2021 08:30 patient ran 99 fever and tired. On 22Sep2021 fever a bit higher and slept all the time. Went to emergency and admitted. Could not find any bacteria infection. Week of 27Sep2021 found he had West Nile Virus. Went on ventilator and hospitalized for 2 weeks. Now inpatient PT have encephalitis. Doctors wonder if vaccine accelerated the virus.. The patient was hospitalized for all events from Sep2021 to Oct2021. Duration of Hospitalization: 16 days. Hospitalization Prolonged. The patient underwent lab tests and procedures which included body temperature: 99 on 21Sep2021, sars-cov-2 test: negative. Therapeutic measures were taken as a result of all events. No other vaccines within 4 weeks prior to the Covid vaccine. The adverse event result in Doctor or other healthcare professional office/clinic visit and Emergency room/department or urgent care. Everything imaginable. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. The outcome of events was not recovered.
wife to get the doses in less than a month.; This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (wife to get the doses in less than a month.) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 15-Sep-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Oct-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (wife to get the doses in less than a month.). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (wife to get the doses in less than a month.) outcome was unknown.            No concomitant and treatment medication were reported.
Chest pain; Feeling hard to breath; Body aches; This spontaneous case was reported by a consumer and describes the occurrence of CHEST PAIN (Chest pain), DYSPNOEA (Feeling hard to breath) and PAIN (Body aches) in a 31-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 034F21A) for COVID-19 vaccination.     The patient's past medical history included COVID-19 (She was not hospitalized, but quarantined herself and stayed home and self-treated) on 19-Aug-2021. Concurrent medical conditions included Anxiety.    On 10-Dec-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Dec-2021, the patient experienced CHEST PAIN (Chest pain), DYSPNOEA (Feeling hard to breath) and PAIN (Body aches). At the time of the report, CHEST PAIN (Chest pain), DYSPNOEA (Feeling hard to breath) and PAIN (Body aches) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 19-Aug-2021, Cardiac function test: not provided Not provided. On 19-Aug-2021, Electrocardiogram: not provided Not provided. On 19-Aug-2021, Myocardial necrosis marker: not provided Not provided. On 19-Aug-2021, SARS-CoV-2 test: positive (Positive) Positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       The patient experienced chest pain, which stared a couple days after vaccination. It was reported that it could be patient's anxiety that caused it and patient stated that it had been going away and coming back, but was not resolved. Patient had body aches, and sometimes feeling hard to breath but not all the time. Patient also stated that the breathing may also be due to anxiety as well. It was reported that the patient had not seek medical attention, but will go to urgent care in the morning of 28 Dec 2021. The patient also intended to receive the vaccine on 29 Dec 2021.  Treatment medication reported included self treatment which was not specified.  No concomitant medications were reported.
CVA requiring tPA converted to SAH, ongoing ICU level of care for at least 2 days as of care rendered to this patient.
pain in joints; This spontaneous case was reported by a consumer and describes the occurrence of ARTHRALGIA (pain in joints) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ARTHRALGIA (pain in joints). At the time of the report, ARTHRALGIA (pain in joints) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.       No concomitant product use was reported  No treatment information was provided   Reporter did not allow further contact
Intermenstrual bleeding despite no menstrual bleeding x years d/t IUD. This occurred within the week after vaccination administration. Severe migraine x 1-2 days after vaccination, followed by congestive headache that has persisted as of 1/13/22. Severe fatigue that began 1-2 days after vaccination and has persisted as of 1/13/22. Please note: my clinic was not the clinic that administered the vaccine.
Covid 19 vaccine was given after beyond use date/expiration date.  Vaccine was maintained at proper storage/handling temperatures. Pfizer and CDC have been contacted and no revaccination is needed.
Information has been received from a Registered Nurse concerning a 60 year old male patient with anti inflammatory agents allergy, who had been admitted to the hospital on 23-SEP-2009 for chronic back pain. On 24-SEP-2009, the patient was vaccinated with a dose of PNEUMOVAX 23 IM and an unspecified influenza virus vaccine given in the same arm. The nurse reported that on 26-SEP-2009 the patient developed a cellulitis reaction. At the time of the report, the patient was still in the hospital but not believed to be prolonged by the cellulitis. The patient had not recovered. The registered nurse considered the cellulitis reaction to be disabling as the patient was unable to move his arm. Follow up information has been received from a Licensed Practical Nurse who reported that she checked with her staff and all physicians and none of them have reported a reaction to PNEUMOVAX 23. Follow up information has been received from the Licensed Practical Nurse concerning the 60 year old male patient with a chronic back pain who on 24-SEP-2009 was vaccinated with a dose of PNEUMOVAX 23 (dose and lot # unknown). Concomitant medication was unspecified. The nurse reported that the original reporter (registered nurse), has never worked at practice and that she did not have information about that adverse event and that the physicians associated with that practice were not aware of a patient with that adverse event. Lab diagnostic studies performed were unspecified. At the time of this report the patient had not recovered. No further information is available.
INFANTILE SPASMS WITH HYPSARRHYTHMIA CONFIRMED BY PHYSICIAN WITNESS OF EVENT COUPLED WITH EEG FINDINGS DEVELOPED 12 HOURS AFTER VACCINATION.  INITIAL EPISODES WERE FIRST CHARACTERIZED AS DYSTONIA BY HISTORY, THEN SANDIFER SYNDROME.  DIAGNOSIS MADE AFTER AN EVENT WAS WITNESSED IN THE OFFICE.  TREATMENT WAS INITIATED ON 6/28/2007 WITH ACTH WITH RESPONSE NOTED.  PATIENT IS STILL UNDERGOING THERAPY.  7/3/07 Hospital medical records received which reveal patient experienced multiple events of posturing followed by crying.  Episodes recurred & were videotaped multiple times over 4 days.  Seen by PCP who dx on 6/25 as Sandifer Syndrome.  Episodes continued & seen by PCP again on 6/28.  Referred to neurologist where witnessed episode was c/w infantile spasms.  Hospitalized 6/28-6/30/07.  No d/c summary dictated per med records. & ACTH theapy was started.    7/24/07 Received vax record which confirms vax info as reported. 1/11/2010 Infintile seizures/spasms thought to be secondary to DTAP vaccine but some disagreement among neurologist on this theory. Child is still having small brief seizures. 02/02/2010 Persistent infantile spasms; side affets of austism, irritability and obesity 20/2 medication. Developmental delay.
This case was reported by a healthcare professional and described the occurrence of trouble catching breath in a male subject of unspecified age who was vaccinated with ENGERIX B (GlaxoSmithKline). In 2011 approximately four to six weeks ago, the subject received unspecified dose of ENGERIX B (unknown route). In 2011 approximately four to six weeks ago, less than one day after vaccination with ENGERIX B, the subject experienced trouble catching breath, "weird" warm sensation in mouth and sensation in his throat. An emergency room visit was required. At the time of reporting the outcome of the events was unspecified. The healthcare professional reported three subjects experienced events with ENGERIX B. See cases A0953068A and A0953069A for details concerning the other two subjects.
Pfizer-BioNTech COVID-19 Vaccine EUA     tiredness; headache; muscle pain; joint pain; fever; nausea; feeling unwell; dizzy; very weak; lack of coordination; equalization off; last 2 fingers on left hand go numb symptoms relieved after 2 1/2 days
I started to notice a metallic taste in my mouth early Saturday morning. Soreness in the arm but it has decreased significantly.
tired for a couple of days; rash at the injection site; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 52 year-old female patient received bnt162b2 (BNT162B2), administered in arm right, administration date 24Apr2021 10:30 (Lot number: ER8736) at the age of 52 years as dose 1, single for covid-19 immunisation. The patient's relevant medical history was not reported. There were no concomitant medications. The following information was reported: VACCINATION SITE RASH (non-serious) with onset 29Apr2021, outcome "not recovered", described as "rash at the injection site"; FATIGUE (non-serious), outcome "unknown", described as "tired for a couple of days".  Additional information: Patient noticed rash at the injection site about the size of a dollar bill. Patient doesn't understand why it came up now. Patient has it marked to see if it gets any bigger but it has stayed about the same. Patient did not administered vaccine from military facility. Patient was not visited to emergency room or physicians office. Patient did not have any prior vaccination within 4 weeks of Covid-19 vaccination.  No follow-up attempts are possible. No further information is expected.
Simple cold; Lost sense of taste; Lost sense of smell; Had mild COVID case after vaccination for five days/ got Covid-19; This spontaneous case was reported by a consumer and describes the occurrence of NASOPHARYNGITIS (Simple cold), AGEUSIA (Lost sense of taste), ANOSMIA (Lost sense of smell) and COVID-19 (Had mild COVID case after vaccination for five days/ got Covid-19) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 13-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Jul-2021, the patient experienced COVID-19 (Had mild COVID case after vaccination for five days/ got Covid-19). On an unknown date, the patient experienced NASOPHARYNGITIS (Simple cold), AGEUSIA (Lost sense of taste) and ANOSMIA (Lost sense of smell). At the time of the report, NASOPHARYNGITIS (Simple cold), AGEUSIA (Lost sense of taste) and ANOSMIA (Lost sense of smell) outcome was unknown and COVID-19 (Had mild COVID case after vaccination for five days/ got Covid-19) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 17-Jul-2021, SARS-CoV-2 test: positive (Positive) Positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication was provided by reporter. No treatment information was provided by reporter.